Home › NDC Lookup › RxCUI directory › RxCUI 1373469

Canagliflozin 100 MG Oral Tablet [Invokana] — RxCUI 1373469

RxNorm drug concept · Semantic branded drug
RxCUI 1373469 Semantic branded drug · SBD ● Current RxNorm concept 5 FDA products 14 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1373469
Official nameCanagliflozin 100 MG Oral Tablet [Invokana]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asInvokana 100 MG Oral Tablet
FDA products mapped5
Package NDCs mapped14
Reported Medicaid activity (SDUD)60,010 prescriptions · 44 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Canagliflozin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Invokana helps lower your blood sugar by making your kidneys pass extra glucose out in your urine rather than keeping it in your blood. On top of that, if you also have heart disea...
  • What exactly is Invokana supposed to do for me if I have type 2 diabetes?
  • This is a real risk worth knowing about. In large clinical trials, people taking Invokana had about twice the rate of lower limb amputations compared to those on placebo — most com...
  • I heard Invokana can cause amputations. How worried should I be?
📖 Read our full Canagliflozin guide →

🕸️ Concept Web — How Canagliflozin 100 MG Oral Tablet [Invokana] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Canagliflozin 100 MG Oral Tablet [Invokana] RxCUI 1373469

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Canagliflozin 1373458
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Invokana 1373464
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Canagliflozin Oral Tablet 1373462
    • Canagliflozin Oral Product 1373460
    • Canagliflozin Pill 1373461
    • Canagliflozin Oral Tablet [Invokana] 1373466
    • Invokana Oral Product 1373467
    • Invokana Pill 1373468
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Canagliflozin 100 MG Oral Tablet SCD · 1373463
  • Canagliflozin 100 MG SCDC · 1373459
  • Canagliflozin Oral Tablet SCDF · 1373462
  • Canagliflozin Oral Product SCDG · 1373460
  • Canagliflozin Pill SCDG · 1373461

Brand-Name Concepts

  • Canagliflozin 100 MG [Invokana] SBDC · 1373465
  • Canagliflozin Oral Tablet [Invokana] SBDF · 1373466
  • Invokana Oral Product SBDG · 1373467
  • Invokana Pill SBDG · 1373468
  • Invokana BN · 1373464

📦 FDA Products & Package NDCs

5 products · 14 package NDCs
14 package NDCs map to RxCUI 1373469 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50090-5034-00 90 TABLET, FILM COATED in 1 BOTTLE (50090-5034-0) INVOKANA A-S Medication Solutions 2020-05-04
50090-5034-01 30 TABLET, FILM COATED in 1 BOTTLE (50090-5034-1) INVOKANA A-S Medication Solutions 2020-05-05
50458-0140-01 5 TABLET, FILM COATED in 1 BOTTLE (50458-140-01) INVOKANA Janssen Pharmaceuticals, Inc. 2013-03-29
50458-0140-10 10 BLISTER PACK in 1 CARTON (50458-140-10) / 10 TABLET, FIL... INVOKANA Janssen Pharmaceuticals, Inc. 2013-03-29
50458-0140-30 30 TABLET, FILM COATED in 1 BOTTLE (50458-140-30) INVOKANA Janssen Pharmaceuticals, Inc. 2013-03-29
50458-0140-50 500 TABLET, FILM COATED in 1 BOTTLE (50458-140-50) INVOKANA Janssen Pharmaceuticals, Inc. 2013-03-29
50458-0140-90 90 TABLET, FILM COATED in 1 BOTTLE (50458-140-90) INVOKANA Janssen Pharmaceuticals, Inc. 2013-03-29
50458-0141-01 5 TABLET, FILM COATED in 1 BOTTLE (50458-141-01) INVOKANA Janssen Pharmaceuticals, Inc. 2013-03-29
50458-0141-10 10 BLISTER PACK in 1 CARTON (50458-141-10) / 10 TABLET, FIL... INVOKANA Janssen Pharmaceuticals, Inc. 2013-03-29
50458-0141-30 30 TABLET, FILM COATED in 1 BOTTLE (50458-141-30) INVOKANA Janssen Pharmaceuticals, Inc. 2013-03-29
50458-0141-50 500 TABLET, FILM COATED in 1 BOTTLE (50458-141-50) INVOKANA Janssen Pharmaceuticals, Inc. 2013-03-29
50458-0141-90 90 TABLET, FILM COATED in 1 BOTTLE (50458-141-90) INVOKANA Janssen Pharmaceuticals, Inc. 2013-03-29
55154-1425-08 2070 TABLET, FILM COATED in 1 BOTTLE (55154-1425-8) INVOKANA Cardinal Health 107, LLC 2013-03-29
55154-1426-08 720 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (55154-1426-8) INVOKANA Cardinal Health 107, LLC 2013-03-29
Observed labelers: Janssen Pharmaceuticals, Inc. (10) · A-S Medication Solutions (2) · Cardinal Health 107, LLC (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.